Transplantation of hematopoietic cells in five patients with chronic granulomatous disease in the Czech Republic

Authors: A. Janda 1;  P. Keslová 1;  R. Formánková 1;  J. Litzman 2;  A. Šedivá 3;  H. Houšťková 4;  P. Rozsíval 5;  E. Pařízková 5;  J. Starý 1;  P. Sedláček 1
Authors‘ workplace: Klinika dětské hematologie a onkologie UK 2. LF a FN Motol, Praha, přednosta prof. MUDr. J. Starý, DrSc., Ústav klinické imunologie a alergologie LF Masarykovy univerzity, FN U sv. Anny, Brno , přednosta prof. MUDr. J. Litzman, CSc., Ústav imunolog 1
Published in: Čes-slov Pediat 2012; 67 (2): 81-88.
Category: Original Papers


Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defective phagocytosis. Conservative treatment is applied in most of the patients. Currently, the only available curative treatment is allogeneic hematopoietic stem cell transplantation (HSCT).

Thirty-seven patients were diagnosed with CGD in the Czech and Slovak Republic between 1957 and 2011. Calculated incidence of the disease in the Czech Republic is 1:280,000 live births. Five patients with serious course of the disease underwent allogeneic HSCT in 2007–2010. Median age of CGD diagnosis in these patients was 6 months (6–17 months), median age at transplantation was 21 months (1–17 years). One patient was transplanted in myeloablative regimen, 4 patients in regimen with reduced intensity. All of the grafts were from HLA-matched unrelated donors. The procedure was complicated with graft versus host disease – GvHD (3 patients), infections (4 patients), autoimmunity (3 patients) and toxic side effects (3 patients). Median follow-up after the transplantation was 12 months (6–44 months). In all of the patients normalization of granulocyte function was documented within 2 months after the transplantation. Mixed chimerism was present in all of them. The oldest patient (transplanted at the age of 17 years, 4 months) died 6 months after transplantation due to intracranial haemorrhage after operational revision of healed brain abscess. All the other patients (4) are in a good clinical condition, without signs of CGD or GvHD.

In concordance with other transplantation centres we show that early allogeneic HSCT is a suitable treatment of patients with severe CGD.

Key words:
chronic granulomatous disease, primary immunodeficiency, hematopoietic stem cell transplantation


1. Roos D, Kuijpers TW, Curnutte J. Chronic granulomatous disease, a molecular and cellular approach. In: Ochs HD, Smith E, Puck JM. Primary Immunodeficiency Diseases. Oxford: Oxford University Press, 2006: 525–549.

2. Kang EM, et al. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol 2011; 127 (6): 1319–1326; quiz 1327–1328.

3. Marciano BE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004; 114 (2): 462–468.

4. Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 2010; 68 (11): 334–340.

5. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol 2008; 140 (3): 255–266.

6. Winkelstein JA, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79 (3): 155–169.

7. Jones LB, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008; 152 (2): 211–218.

8. van den Berg JM, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4 (4): e5234.

9. Kuhns DB, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363 (27): 2600–2610.

10. Banerjee R, et al. Cutting edge: infection by the agent of human granulocytic ehrlichiosis prevents the respiratory burst by down-regulating gp91phox. J Immunol 2000; 164 (8): 3946–3949.

11. Honzík T, et al. Prolonged impairment of polymorphonuclear cells functions in one infant with transient zinc deficiency: A case report. Prague Med Rep 2008; 109 (2–3): 184–193.

12. Seger RA. Advances in the diagnosis and treatment of chronic granulomatous disease. Curr Opin Hematol 2011; 18 (1): 36–41.

13. Stein S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16 (2): 198–204.

14. Seger RA. Hematopoietic stem cell transplantation for chronic granulomatous disease. Immunol Allergy Clin North Am 2010; 30 (2): 195–208.

15. Janda A. Pacienti s chronickou granulomatózní nemocí v České a Slovenské republice. Alergie 2010; 12 (2): 112–120.

16. Reichenbach J, et al. Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis 2009; 49 (11): 1703–1710.

17. Cale CM, Mortonand L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 2007; 148 (1): 79–84.

Neonatology Paediatrics General practitioner for children and adolescents
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account